Gilead Sciences Portfolio holdings
Gilead Sciences is an American biopharmaceutical company that researches and develops antiviral drugs for HIV/AIDS, hepatitis B and C, influenza and COVID-19. Michael Riordan, a doctor who was then an associate at the venture firm Menlo Ventures, founded it in 1987 as Oligogen, a name pointing to oligonucleotides, small strands of DNA. Riordan used Oligogen only while clearing a trademark issue with a California nonprofit, and he took the Gilead name from the Balm of Gilead, which he first met in a Lanford Wilson play. Gilead discovered the flu drug Tamiflu and licensed it to Roche, and its 2011 purchase of Pharmasset brought it sofosbuvir, approved in 2013 as the hepatitis C treatment Sovaldi. In 2017 Gilead said it would acquire Kite Pharma as its entry into cell therapy, a deal that had produced two lymphoma treatments, Yescarta and Tecartus, by 2022.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcellx
ACLX
|
+$581M |
| 2 |
Arcus Biosciences
RCUS
|
+$491M |
| 3 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$466M |
| 4 |
Assembly Biosciences
ASMB
|
+$35.6M |
| 5 |
Tango Therapeutics
TNGX
|
+$22.5M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.01% |
| 2 | Financials | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Arcellx
ACLX
| $515M | 33.23% |
+6,720,803
| New | +$581M |
2024 Q4
0 quarters
|
|
|
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.13B
| $462M | 29.77% |
+16,707,477
| New | +$466M |
2024 Q4
0 quarters
|
|
|
3
Arcus Biosciences
RCUS
$2.32B
| $448M | 28.86% |
+30,061,124
| New | +$491M |
2024 Q4
0 quarters
|
|
|
4
Assembly Biosciences
ASMB
$410M
| $34.9M | 2.25% |
+2,209,471
| New | +$35.6M |
2024 Q4
0 quarters
|
|
5
DELISTED
Merus
MRUS
| $19M | 1.23% |
+452,527
| New | +$21.7M |
2024 Q4
0 quarters
|
|
6
Kyverna Therapeutics
KYTX
$351M
| $15.4M | 0.99% |
+4,126,119
| New | +$19.8M |
2024 Q4
0 quarters
|
|
7
Cypherpunk Technologies Inc
CYPH
$321M
| $15.3M | 0.99% |
+5,319,148
| New | +$15.8M |
2024 Q4
0 quarters
|
|
|
8
Tango Therapeutics
TNGX
$3.83B
| $15M | 0.97% |
+4,854,443
| New | +$22.5M |
2024 Q4
0 quarters
|
|
9
Xilio Therapeutics
XLO
$52.8M
| $8.7M | 0.56% |
+650,389
| New | +$8.95M |
2024 Q4
0 quarters
|
|
10
Kalaris Therapeutics
KLRS
$48.3M
| $6.99M | 0.45% |
+723,273
| New | +$10.9M |
2024 Q4
0 quarters
|
|
11
DELISTED
HOOKIPA Pharma
HOOK
| $3.77M | 0.24% |
+1,875,945
| New | +$5.8M |
2024 Q4
0 quarters
|
|
12
ImageneBio Inc
IMA
$46.5M
| $3.29M | 0.21% |
+167,362
| New | +$3.38M |
2024 Q4
0 quarters
|
|
13
Allogene Therapeutics
ALLO
$408M
| $2.46M | 0.16% |
+1,156,689
| New | +$2.85M |
2024 Q4
0 quarters
|
|
|
BRNS
14
DELISTED
Barinthus Biotherapeutics
BRNS
| $749K | 0.05% |
+620,351
| New | +$722K |
2024 Q4
0 quarters
|
|
15
Agenus
AGEN
$309M
| $635K | 0.04% |
+231,663
| New | +$858K |
2024 Q4
0 quarters
|
|
16
DELISTED
Kronos Bio
KRON
| $179K | 0.01% |
+188,567
| New | +$178K |
2024 Q4
0 quarters
|
|
Similar funds
Gilead Sciences's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Gilead Sciences, which disclosed 16 positions worth $1.55B. Its ten largest holdings account for 99% of the portfolio.
Its largest position is Arcellx: 6,720,803 shares worth $515M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, followed by Financials.
- Gilead Sciences's largest Q4 2024 buy was Arcellx: 6,720,803 shares worth $515M.
- Gilead Sciences's ten largest holdings make up 99% of its $1.55B portfolio in Q4 2024.
- Gilead Sciences disclosed 16 positions in Q4 2024, its first 13F filing on record.
Based on Gilead Sciences's 13F filing for Q4 2024, filed 13 Feb 2025.